miRNAs mediated drug resistance in hematological malignancies
SP da Silva, HR Caires, R Bergantim… - Seminars in Cancer …, 2022 - Elsevier
Despite improvements in the therapeutic approaches for hematological malignancies in the
last decades, refractory disease still occurs, and cancer drug resistance still remains a major …
last decades, refractory disease still occurs, and cancer drug resistance still remains a major …
A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy
P Xue, G Zhang, H Zhang, S Cui… - Journal of Cellular …, 2022 - Wiley Online Library
Platinum‐based chemotherapy is regarded as a preferential curative‐intent option for non‐
small cell lung cancer (NSCLC), while the acquired drug resistance has become a major …
small cell lung cancer (NSCLC), while the acquired drug resistance has become a major …
[HTML][HTML] Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: A prospective cohort study
Excision repair complementary complex 5 (ERCC5) is an important component in the repair
pathway of platinum-induced damage. The current study evaluated the effect of ERCC5 …
pathway of platinum-induced damage. The current study evaluated the effect of ERCC5 …